Item 9 Labs Stock Price, News & Analysis
Company Description
Item 9 Labs (OTC Link: INLB) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $10.2K.
INLB stock has gained 0.0% over the past year. Shares last traded at $0.0000.
On a trailing twelve-month basis, Item 9 Labs reported revenue of $21.8M with net income of -$31.2M and diluted earnings per share of $-0.33. The company operates at a net profit margin of -143.3%.
This page provides a comprehensive overview of INLB stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Item 9 Labs (INLB) stock last traded at $0.0000. At a market capitalization of $10.2K, INLB is classified as a micro-cap stock with approximately 102.4M shares outstanding.
Latest News
Item 9 Labs has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include conferences. View all INLB news →
SEC Filings
Financial Highlights
Item 9 Labs generated $21.8M in revenue over the trailing twelve months, retaining a 33.6% gross margin, operating income reached -$23.1M (-106.0% operating margin), and net income was -$31.2M, reflecting a -143.3% net profit margin. Diluted earnings per share stood at $-0.33. The company generated -$2.3M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
INLB Company Profile & Sector Positioning
Item 9 Labs (INLB) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing INLB often look at related companies in the same sector, including Halo Collective Inc (HCANF), Avivagen (VIVXF), Bloomios Inc (BLMS), Veritas Farms (VFRM), and Onassis Holdings Corp (ONSS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INLB's relative position within its industry.